Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BIBW 2992

Known as: BIBW-2992, BIBW2992 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
To overcome T790M-mediated acquired resistance of lung cancer cells to epidermal growth factor receptor tyrosine kinase… Expand
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
The secondary EGF receptor (EGFR) T790M is the most common mechanism of resistance to reversible EGFR-tyrosine kinase inhibitors… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members… Expand
  • table 1
  • table 2
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
2011
2011
Afatinib (BIBW 2992), a novel aniline-quinazoline derivative, irreversibly and equipotently targets the intrinsic kinase activity… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Preclinical data have demonstrated that BIBW 2992 is a potent irreversible inhibitor of ErbB1 (EGFR/HER1) and mutated… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2008
Review
2008
The anilino-quinazoline derivative BIBW-2992, which is being developed by Boehringer Ingelheim Corp for the potential treatment… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of the dual epidermal growth factor… Expand
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
2007
2007
Purpose:To investigate the effect of the dual EGFR/HER2 (ErbB2) tyrosine kinase inhibitors BIBW 2992 and BIBW 2669 on… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?